Eli Lilly reports 62% cholesterol reduction in Phase 1 trial of Verve gene-editing therapy
Early data from a Phase 1 study of VERVE-102, a base-editing therapy targeting PCSK9, show substantial LDL-cholesterol reductions at high doses, though the therapy remains at an early investigational stage.
Eli Lilly has reported Phase 1 clinical trial data for VERVE-102, a gene-editing therapy developed in partnership with Verve Therapeutics that uses adenine base editing to permanently reduce expression of PCSK9 in the liver. At the highest dose tested, participants showed a mean 62% reduction in LDL-cholesterol levels, according to data disclosed by Lilly on 25 May 2026 and reported by STAT News.
VERVE-102 is delivered via lipid nanoparticles and is designed to make a single nucleotide change in the PCSK9 gene rather than introducing a double-strand break, a design choice intended to reduce the risk of unintended genomic alterations. The therapy targets the same biological pathway as the existing class of injectable PCSK9 inhibitor antibodies, but aims to achieve a durable effect from a single administration.
The Phase 1 trial is a first-in-human safety and dose-finding study; the 62% figure comes from a small number of participants at the highest dose cohort. Longer-term durability data, a full safety profile, and larger trial cohorts will be necessary before the approach can be assessed for broader use. Regulatory approval is many years away. Researchers and analysts have noted the result as encouraging for the base-editing field, though the Phase 1 context means considerable uncertainty remains about efficacy and safety at scale.
The disclosure follows Lilly's broader expansion into gene-editing approaches for cardiometabolic disease, including several acquisitions of vaccine and biotechnology developers announced in the same week.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
Scientists at a company called Eli Lilly have shared early results from a small clinical trial of a new gene-editing treatment aimed at lowering harmful cholesterol in the blood. The treatment, called VERVE-102, uses a technique called base editing to make a tiny, permanent change to a gene in the liver called PCSK9, which normally helps control cholesterol levels. In the trial, people who received the highest dose saw their LDL (sometimes called 'bad') cholesterol fall by around 62% on average.
This is a very early-stage trial — its main purpose is to check that the treatment is safe and to find the right dose, not to prove it works in large numbers of people. Much more research is needed before any gene-editing treatment for cholesterol could become available to patients. Researchers say the result is an encouraging sign for the field, but it is not yet known whether the benefits last long-term or what the full safety profile looks like.
This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source Stat News · 2026-05-25Eli Lilly says Verve's gene editor lowers cholesterol levels in early study
-
Stat News · 2026-05-26Pharmalittle: We're reading about a Lilly gene therapy for cholesterol, three new Lilly deals, and more